This is because high PD-L1 expression allows tumor cells to evade immune surveillance more effectively, whereas pembrolizumab blocks the PD-1/PD-L1 pathway, restoring immune system activity against tumor cells (168). This evidence concerns the gene CD274 and neoplasm.